Biogennix
- Company typePrivate
- Founded2009
- HeadquartersIrvine, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Biogennix firmographics
Firmographics- Name
- Biogennix
- Legal name
- Biogennix, LLC.
- Website
- https://biogennix.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biogennix industry classification
Industry- Product category
- Orthopedic Bone Graft Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Biogennix is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biogennix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Synthetic Bone Graft Products: Biogennix designs, manufactures, and distributes advanced synthetic bone graft products for orthopedic and spine surgery. Products are sold through a distributor network to healthcare providers and surgeons.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Biogennix product offering
Product offeringCore offering
Biogennix designs, manufactures, and distributes advanced synthetic bone graft products and an associated stem cell harvesting system for orthopedic, spine, and foot and ankle surgeons. Its product portfolio — built on the proprietary TrelCor® nanocrystalline hydroxycarbanoapatite (HCA) platform — includes posterolateral spinal fusion blocks, moldable and strip bone grafts, a collagen surgical matrix, and an autograft harvesting system, all sold exclusively through authorized U.S. distributors.
Product overview
Biogennix is a medical device company founded in 2009, focused on advanced synthetic bone graft products for orthopedic and spine surgery. The company offers a portfolio of bone grafting solutions based on proprietary TrelCor® technology featuring nanocrystalline HCA surface and biomimetic pore architecture. The product line includes: osteoSPAN™ Fusion Kit (posterolateral spinal fusion blocks), Morpheus® Moldable (synthetic moldable graft), Agilon® Moldable and Strip (collagen-enhanced bone grafts), Agilon® Surgical Matrix (collagen wound care), and DirectCell® System (stem cell harvesting system). All products share the TrelCor technology platform enabling bone regeneration through osteoconductive scaffolds without supplemental cells or growth factors.
Differentiator
Problem solved
Functional benefit
Brands
- Agilon®: Collagen-enhanced synthetic bone graft product line including Moldable, Strip, and Surgical Matrix configurations, developed with proprietary TrelCor® technology.
- osteoSPAN™
- Morpheus®
- DirectCell®
- TrelCor®
Products and services
- osteoSPAN™ Fusion Kit Posterolateral spinal fusion kit consisting of two porous blocks (6x9x40mm or 6x6x40mm) designed with continuous interconnected porosity to bridge transverse processes, based on TrelCor technology with dual-phase HCA/calcium carbonate chemistry and a 6-12 month resorption profile. Intended for spine surgeons performing posterolateral fusion procedures.
- Agilon® Moldable Moldable collagen-enhanced synthetic bone graft consisting of 1-2mm TrelCor granules suspended in an organic binder with Type 1 bovine collagen, featuring firm yet moldable consistency, 1-2 day binder absorption, and a 6-12 month granule resorption profile. Targeted at orthopedic and spine surgeons needing a moldable graft for irregular defects.
- Agilon® Strip Collagen-enhanced bone graft strip made of resorbable TrelCor granules densely packed in a Type 1 bovine collagen matrix, with 500 micron pore size, high compression resistance, rapid fluid absorption, and flexible strip configuration for voids and defects. Designed for surgeons filling linear defects and voids.
- Agilon® Surgical Matrix Wound care solution derived from 100% bovine Type 1 collagen that transforms into a gel upon contact with wounds, maintaining a moist low-pH environment for granulation tissue formation and epithelialization, with demonstrated antimicrobial properties. Targeted at surgeons managing surgical and chronic wounds.
- Morpheus® Moldable Synthetic moldable bone graft composed of 1-2mm TrelCor granules in a rapidly absorbing organic binder, engineered for optimal handling with a dual-phase resorption profile over 6-12 months. Targeted at surgeons requiring a fully synthetic (non-collagen) moldable bone graft.
- DirectCell® System Advanced bone grafting system enabling spin-free stem cell aspirate harvesting via a patented screw mechanism for multi-directional harvesting and a blocked tip design to minimize peripheral blood collection; includes Agilon Moldable or Agilon Strip with TrelCor granules. Backed by over 50,000 successful cases and intended for surgeons performing stem cell and autograft harvesting.
Companies that use Biogennix
Customer profileSegments3 records
Ideal customer profiles3 records
Biogennix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Biogennix partnerships and signals
Strategic signalScale indicators2 records
Recent moves1 record
Expansion highlights4 records
Biogennix competitors and assessment
Company assessmentBroad incumbents
- DePuy Synthes (Johnson & Johnson): Broad orthopedic and spine portfolio including bone graft substitutes used in trauma and spine fusion procedures; competes with Biogennix across multiple surgical call points.
- Medtronic: Dominant spine hardware incumbent with the Infuse Bone Graft (rhBMP-2) biologic franchise; bundles bone graft substitutes with its broad spine implant portfolio, competing with Biogennix for spine surgeon share.
- Globus Medical (formerly NuVasive): Large spine-focused company offering bone graft substitutes and spine hardware as a bundled solution, directly competitive with Biogennix's osteoSPAN and synthetic graft offerings in the spine fusion market.
- Stryker: Major orthopedic and spine player with bone graft substitute offerings (e.g., Vitoss) as part of a much wider surgical and orthobiologics portfolio; competes with Biogennix for hospital bone graft budgets.
- Orthofix: Spine and orthopedic company with bone growth stimulation and biologic products used in fusion procedures; competes with Biogennix in the broader bone healing and regeneration category.
Direct peers
- Cerapedics: Developer of peptide-enhanced bone graft (i-FACTOR) for cervical spine fusion — a direct competitor in the synthetic bone graft substitute category targeting spine surgeons, the same primary call point as Biogennix.
- SeaSpine: Pure-play spine surgery company with a dedicated orthobiologics portfolio including demineralized bone matrices and synthetic bone grafts directly competitive with Biogennix's TrelCor-based spine products.
- Xtant Medical: Focused orthobiologics company offering synthetic and allograft bone graft substitutes for spine and orthopedic procedures, competing head-to-head with Biogennix in synthetic bone graft channels.
Emerging players
- Locate Bio: Smaller orthobiologics company developing next-generation bone graft and regenerative medicine technologies that compete in the synthetic and biologic bone graft space alongside Biogennix.
- SurGenTec: Emerging osteobiologics and spine company offering bone graft substitutes and minimally invasive delivery systems targeting similar spine and orthopedic indications as Biogennix.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Biogennix social profiles
Digital presenceBiogennix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biogennix leadership team
Management profileNumber of profiles
Profiles1 record
Biogennix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biogennix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biogennix
What does Biogennix do?
Biogennix designs, manufactures, and distributes advanced synthetic bone graft products and an associated stem cell harvesting system for orthopedic, spine, and foot and ankle surgeons. Its product portfolio — built on the proprietary TrelCor® nanocrystalline hydroxycarbanoapatite (HCA) platform — includes posterolateral spinal fusion blocks, moldable and strip bone grafts, a collagen surgical matrix, and an autograft harvesting system, all sold exclusively through authorized U.S. distributors.
Is Biogennix a public or private company?
Biogennix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biogennix founded?
Biogennix was founded in 2009. It employs 11 to 50 people.
Where is Biogennix based?
Biogennix is headquartered in Irvine, United States, in the North America region.
How does Biogennix make money?
One revenue line is on record: synthetic Bone Graft Products.
Who are Biogennix's main competitors?
Broad incumbents on record are DePuy Synthes (Johnson & Johnson), Medtronic, Globus Medical (formerly NuVasive), Stryker and Orthofix. Direct peers are Cerapedics, SeaSpine and Xtant Medical. Emerging players are Locate Bio and SurGenTec.
Does Biogennix have an API?
No public API is recorded for Biogennix.
What industry is Biogennix in?
Biogennix's product category is Orthopedic Bone Graft Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.